12:00 AM
 | 
Mar 08, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Onrigin laromustine regulatory update

Vion said FDA has requested that the company conduct an additional Phase II trial evaluating Onrigin laromustine as a remission induction therapy in patients ages 60 and up with de novo, poor-risk...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >